Overview

• RO76 targets an unconventional spot on the opioid receptor, reducing respiratory depression compared to morphine.
• The compound successfully crosses the blood-brain barrier, essential for effective pain relief.
• In animal tests, RO76 demonstrated similar pain-suppressing effects to morphine but with fewer withdrawal symptoms.
• The new derivative shows potential for development as an oral medication for humans.
• Research was conducted by teams from Washington University, University of Florida, and Stanford University.